BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.61 Decreased By ▼ -0.39 (-0.74%)
BOP 34.23 Increased By ▲ 0.24 (0.71%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.23 Increased By ▲ 0.03 (0.25%)
FCCL 53.80 Increased By ▲ 0.97 (1.84%)
FCSC 5.24 Increased By ▲ 0.17 (3.35%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.07 Increased By ▲ 0.05 (0.62%)
KOSM 5.39 Decreased By ▼ -0.13 (-2.36%)
MLCF 87.90 Increased By ▲ 1.39 (1.61%)
NBP 186.60 Increased By ▲ 1.44 (0.78%)
PACE 10.75 Increased By ▲ 0.17 (1.61%)
PAEL 39.95 Increased By ▲ 0.53 (1.34%)
PIAHCLA 26.19 Decreased By ▼ -0.03 (-0.11%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 233.49 Increased By ▲ 5.31 (2.33%)
PRL 34.98 Increased By ▲ 0.30 (0.87%)
PTC 67.71 Increased By ▲ 2.38 (3.64%)
SEARL 90.90 Increased By ▲ 0.77 (0.85%)
SSGC 27.20 Increased By ▲ 0.60 (2.26%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.85 Increased By ▲ 2.35 (4.02%)
TPLP 8.78 Increased By ▲ 0.56 (6.81%)
TREET 24.65 Increased By ▲ 0.12 (0.49%)
TRG 71.50 Increased By ▲ 1.79 (2.57%)
WAVES 10.01 Increased By ▲ 0.07 (0.7%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
World

US cancels $590 million contract with Moderna for bird flu shot

Published May 29, 2025 Updated May 29, 2025 10:38am
Photo: Reuters
Photo: Reuters
By

WASHINGTON: US President Donald Trump’s administration on Wednesday canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said.

It marked the latest move against vaccines by Health Secretary Robert F. Kennedy Jr, who has spent decades promoting misinformation about immunization.

The contract, announced on January 17 – three days before Trump took office – was for an mRNA vaccine targeting the H5N1 influenza strain, which has been circulating in birds and cattle.

Experts have warned the virus could jump to humans and spark a pandemic.

American pharmaceutical and biotechnology company Moderna disclosed the news as it announced positive results from an early stage clinical trial of 300 people designed to test safety and immune response.

Moderna beats COVID vaccine sales expectations as deferred revenue rolls in

“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,” said CEO Stephane Bancel in a statement.

“These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.”

The statement added Moderna would “explore alternatives” for funding the development and manufacturing of the vaccine.

Dr. Ashish Jha, a public health expert who served as former president Joe Biden’s Covid-19 response coordinator, reacted with dismay.

“The attack on mRNA vaccines is beyond absurd,” he posted on X. “It was President Trump’s Operation Warp Speed that gave us mRNA vaccines.”

Comments

Comments are closed for this article.